Humacyte
Stock Forecast, Prediction & Price Target
Humacyte Financial Estimates
Humacyte Revenue Estimates
Humacyte EBITDA Estimates
Humacyte Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.26M N/A | $1.56M 23.91% | $0 -100% | Avg: $30.14M Low: $17.30M High: $39.34M avg. 0% | Avg: $92.23M Low: $52.95M High: $120.41M avg. 206.01% | Avg: $218.81M Low: $125.62M High: $285.66M avg. 137.24% | Avg: $365.34M Low: $209.75M High: $476.96M avg. 66.96% |
Net Income
% change YoY
| $37.53M N/A | $64.21M 71.08% | $-110.77M -272.49% | Avg: $-98.34M Low: $-100.31M High: $-66.18M avg. 11.22% | Avg: $-49.81M Low: $-63.08M High: $4.13M avg. 49.35% | Avg: $-4.65M Low: $-6.50M High: $-2.07M avg. 90.65% | Avg: $55.84M Low: $24.92M High: $78.02M avg. 1300.00% |
EBITDA
% change YoY
| $-136.98M N/A | $-160.34M -17.05% | $-96.45M 39.84% | Avg: $-18.08M Low: $-23.60M High: $-10.38M avg. 81.25% | Avg: $-55.33M Low: $-72.24M High: $-31.77M avg. -206.01% | Avg: $-131.29M Low: $-171.40M High: $-75.37M avg. -137.24% | Avg: $-219.20M Low: $-286.17M High: $-125.85M avg. -66.96% |
EPS
% change YoY
| $0.94 N/A | $0.62 -34.04% | -$1.07 -272.58% | Avg: -$0.8 Low: -$0.97 High: -$0.64 avg. 25.07% | Avg: -$0.37 Low: -$0.61 High: $0.04 avg. 54.09% | Avg: -$0.05 Low: -$0.06 High: -$0.02 avg. 87.77% | Avg: $0.54 Low: $0.24 High: $0.75 avg. 1300.00% |
Operating Expenses
% change YoY
| $81.20M N/A | $84.57M 4.14% | $23.49M -72.21% | Avg: $259.44M Low: $148.95M High: $338.70M avg. 1004.14% | Avg: $793.92M Low: $455.80M High: $1.03B avg. 206.01% | Avg: $1.88B Low: $1.08B High: $2.45B avg. 137.24% | Avg: $3.14B Low: $1.80B High: $4.10B avg. 66.96% |
FAQ
What is Humacyte stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 362.80% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -100.31M, average is -98.34M and high is -66.18M.
What is Humacyte stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 102.55% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $17.30M, average is $30.14M and high is $39.34M.
What is Humacyte stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 366.73% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.97, average is -$0.8 and high is $-0.64.
What is the best performing analyst?
In the last twelve months analysts have been covering Humacyte stock. The most successful analyst is Matt O'Brien whose win rate is 50%. He has correctly predicted 1/2 price targets.